AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited-stage small cell lung cancer
1. Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. ...
Tag: lung cancer
RAMOSE Phase II trial finds promising results for osimertinib and ramucirumab in non-small cell lung cancer
1. Treatment of patients with tyrosine kinase inhibitor (TKI)-naïve epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with ...
Amivantumab plus lazertinib improves survival in EGFR-mutated advanced NSCLC
1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung ...
Adjuvant durvalumab therapy improves survival in limited-stage small cell lung cancer
1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo ...
Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer
1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade ...
#VisualAbstract Telehealth vs In-Person Early Palliative Care for Patients with Advanced Lung Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
TKI With or Without SRS for Brain Metastases From EGFR/ALK Mutated NSCLC
1. Median overall survival was 41 months in the TKI-only group vs 40 months in the TKI-SRS group, with HR ...
AstraZeneca’s Tagrisso and chemotherapy pairing have been approved in Canada for treatment in locally advanced or metastatic non-small cell lung cancer.
Tagrisso is the first-line therapy for patients whose lung cancer tumors have EGFR exon 19 deletions or exon 21 substitution ...
Johnson and Johnson: The subcutaneous formulation of Rybrevant was more effective than the intravenous formulation in reducing the risk of death in lung cancer patients.
The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination ...